ZYNLONTA (loncastuximab tesirine-lpyl) — Regulatory decision
2026
The Company is also evaluating a regulatory pathway for this combination and plan to submit for Breakthrough Therapy designation ("BTD") this year.Source filing
ADCT biotech catalysts & pipeline
ADC THERAPEUTICS SA · Data as of 2026-10-25
Upcoming catalysts
ZYNLONTA (loncastuximab tesirine-lpyl) — NDA/BLA submission
2026
We look forward to the presentation of the LOTIS-5, LOTIS-7 and MZL investigator-initiated trial data later this year and expect submission for publication.Source filing
ZYNLONTA (loncastuximab tesirine-lpyl) — Regulatory filing (type unspecified)
2026
The Company is also evaluating a regulatory pathway for this combination and plans to submit for Breakthrough Therapy designation (BTD) this year.Source filing
ZYNLONTA (loncastuximab tesirine-lpyl) — NDA/BLA submission
Q4 2026
ADC Therapeutics expects to submit an sBLA in the fourth quarter of 2026.Source filing
ZYNLONTA (loncastuximab tesirine-lpyl) — Conference presentation
Dec 12–Dec 15
"These efforts extend our expected cash runway and increase strategic optionality, as we approach much anticipated LOTIS-7 and MZL data abstracts in early November with presentations in December at the 68th American Society of Hematology Annual Meeting."Source filing